$27.03−0.10 (−0.37%)
At close: Oct 26, 2026, 4:00 PM ET· Nasdaq · USD
Ceribell (CBLL) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~40.3%/yr (FY23→FY25), net margin −60.0%.
The four lines that matter · FY23–FY25
Revenue ($M)▲36.1%
89.1
FY23→FY25CAGR +40.3%/yr
Net income ($M)▼32.0%
−53.4
FY23→FY25CAGR —
Free cash flow ($M)▼14.3%
−41.6
FY23→FY25CAGR —
Diluted EPS▲56.9%
−1.46
FY23→FY25CAGR —
What the income statement says · FY23–FY25
Where every revenue dollar goes · FY25 ($M)
-60¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 84.4% → 87.9%. Net margin -60.0% is below the sector median.
The receipt · income statement · FY23–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | YoY | CAGR 23→25 |
|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||
Revenue | 101,964.0 | 89,063.0 | 65,444.0 | 45,225.0 | ▲36.1% | +40.3% |
Cost of revenue | 11,319.0 | 10,789.0 | 8,694.0 | 7,062.0 | ▲24.1% | +23.6% |
Gross profit | 90,645.0 | 78,274.0 | 56,750.0 | 38,163.0 | ▲37.9% | +43.2% |
Research & development | 22,953.0 | 19,143.0 | 13,562.0 | 8,995.0 | ▲41.2% | +45.9% |
Selling, general & admin | 53,229.0 | 44,451.0 | 33,842.0 | 20,287.0 | ▲31.3% | +48.0% |
Total operating expenses | 160,614.0 | 136,676.0 | 96,459.0 | 68,204.0 | ▲41.7% | +41.6% |
Operating incomefeeds ROC rank | −69,969.0 | −58,402.0 | −39,709.0 | −30,041.0 | ▼47.1% | — |
Other income, net | 3,972.0 | 4,990.0 | −746.0 | 588.0 | — | — |
Pretax income | −65,997.0 | −53,412.0 | −40,455.0 | −29,453.0 | ▼32.0% | — |
Income tax | — | 0.0 | 0.0 | 11.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −65,997.0 | −53,412.0 | −40,455.0 | −29,464.0 | ▼32.0% | — |
| Per share | ||||||
Diluted EPSbuyback-sensitive | −1.75 | −1.46 | −3.39 | −5.56 | ▲56.9% | — |
Diluted shares (mn) | 38.03 | 36.54 | 11.95 | 5.30 | ▲205.8% | +162.5% |
| Margins | ||||||
Gross margin69th pct in Healthcare | 88.9% | 87.9% | 86.7% | 84.4% | ▲1.2pp | +3.5pp |
Operating margin | −68.6% | −65.6% | −60.7% | −66.4% | ▼4.9pp | +0.9pp |
Net margin25th pct in Healthcare | −64.7% | −60.0% | −61.8% | −65.1% | ▲1.8pp | +5.2pp |
† TTM = trailing four quarters through 2026-06-30.
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Ceribell's revenue last fiscal year?
Ceribell reported revenue of $89.1M in fiscal 2025, up 36.1% from fiscal 2024.
What was Ceribell's net income?
Ceribell reported net income of −$53.4M in fiscal 2025, a net margin of −60.0%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.